On September 10, 2025, UBS raised its price target for UnitedHealth Group Incorporated (NYSE:UNH) from $330 to $378, maintaining a ‘Buy’ rating. The upgrade followed reaffirmation of 2025 guidance and confirmation of steady Stars ratings through 2027. UBS acknowledged risks from v28 Medicare Advantage changes in 2026 but cited management’s margin-strengthening efforts as supportive of continued growth.
UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare services worldwide through its UnitedHealthcare insurance arm and Optum’s analytics, pharmacy, and care delivery businesses. It is one of the Best Diversified Stocks.
While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.